You are on Trendlyne India. Click here to go to United States website or make India as your default

Beta Drugs Ltd. NSE: BETA | BSE: 531481

Beta Drugs Ltd. Live Share Price Today, Share Analysis and Chart

1914.00 51.70 (2.78%)

82.70% Gain from 52W Low

945 NSE Volume

NSE 21 Apr, 2025 2:48 PM (IST)

Loading... You have run out of DVM views! Check usage
Subscribe now to see details
Not Eligible
-
Expensive Valuation
9.3 / 100
Technically Neutral
55.4 / 100

Beta Drugs Live Price Chart

Switch to TradingView
Fetching data ...

Beta Drugs Stock Analysis

Beta Drugs stock analysis with key metrics, changes, and trends.

Beta Drugs MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue₹297.07 Cr30.37%positive

Annual Revenue rose 30.37%, in the last year to ₹297.07 Cr. Its sector's average revenue growth for the last fiscal year was 11.87%.

Annual Net Profit₹36.44 Cr18.62%positive

Annual Net Profit rose 18.62% in the last year to ₹36.44 Cr. Its sector's average net profit growth for the last fiscal year was 26.81%.

Price to Earning Ratio53.03-negative

Price to Earning Ratio is 53.03, higher than its sector PE ratio of 40.07.

Stock Price₹1914.0043.7%positive

Stock Price rose 43.7% and outperformed its sector by 20.07% in the past year.

Debt to Equity Ratio0.07-positive

Debt to Equity Ratio of 0.07 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)23.19 %23.19%positive

Return on Equity(ROE) for the last financial year was 23.19%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.00 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0%.

Promoter Share Holding66.73 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 66.73%.

Interest Coverage Ratio21.76-positive

Interest Coverage Ratio is 21.76, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Promoter Pledges0.00 %0%positive

Promoter Pledges are zero.

VIEW LESS


Loading data..

Beta Drugs Ltd. - Company Profile

What does Beta Drugs Ltd. do?

Beta Drugs is engaged the The company is in the business of manufacturing of Oncology Medicines.

Website: www.betadrugslimited.com

Beta Drugs Ltd. Management structure

All Gross Remunerations are in INR
Mr. Nipun Arora
Chief Financial Officer
31.01 Lac
2024-3-31
Gross Remuneration
Year
Rajni Brar
Company Secretary, Compliance Officer
9.12 Lac
2024-3-31
Gross Remuneration
Year

Beta Drugs Ltd. Board of directors

All Gross Remunerations are in INR
Varun Batra
Joint Managing Director
1.21 Cr
2024
Gross Remuneration
Year
Rahul Batra
Chairperson & M D
1.21 Cr
2024
Gross Remuneration
Year
Ashutosh Shukla
Whole-time Director
51.23 Lac
2024
Gross Remuneration
Year
Balwant Singh.
Whole-time Director
29.8 Lac
2024
Gross Remuneration
Year
Rajni Brar
Company Sec. & Compli. Officer
9.12 Lac
2024
Gross Remuneration
Year
Manmohan Khanna
Independent Director
-
2024
Gross Remuneration
Year

Beta Drugs Ltd. - company history

Beta Drugs Limited was incorporated as a private limited company with the name "Beta Drugs Private limited" at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to "Beta Drugs Limited" on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Company's products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new "state of the art" manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores. The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEM-RTU, ADLEAP, ADLANTE, BEXINIB; launched 1st Indian Brand of Dasatinib, BEEDAN. In 2021, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.

Beta Drugs Ltd. FAQ

How is Beta Drugs Ltd. today?
Beta Drugs Ltd. today is trading in the green, and is up by 2.78% at 1914.00.
Beta Drugs Ltd. is currently trading up 2.78% on an intraday basis. In the past week the stock rose 3.46%. stock has been up 5.50% in the past quarter and rose 43.70% in the past year. You can view this in the overview section.